Cytek Biosciences (CTKB)
(Delayed Data from NSDQ)
$5.30 USD
-0.05 (-0.93%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $5.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Cytek Biosciences, Inc. (CTKB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.80 | $12.00 | $8.00 | 83.18% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Cytek Biosciences, Inc. comes to $9.80. The forecasts range from a low of $8.00 to a high of $12.00. The average price target represents an increase of 83.18% from the last closing price of $5.35.
Analyst Price Targets (5 )
Broker Rating
Cytek Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 66.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CTKB.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Steven Mah | Strong Buy | Strong Buy |
2/29/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
1/26/2024 | Raymond James | Andrew Cooper | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 6 |
Average Target Price | $9.80 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 72 of 253 |
Current Quarter EPS Est: | -0.01 |